Vanda, Nektar get thumbs down from CHMP

EMA’s CHMP adopted negative opinions on drug candidates from Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) and Nektar Therapeutics (NASDAQ:NKTR).

Regarding an MAA for Vanda's Fanaptum iloperidone to treat schizophrenia, the committee said the candidate's efficacy was "modest," noted an increased risk of QT prolongation, and concluded that Fanaptum's benefits did not outweigh its risks. Vanda intends to request a re-examination of the MAA...